228 related articles for article (PubMed ID: 28758810)
41. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
42. Leuprorelin acetate depot: results of a multicentre Japanese trial. TAP-144-SR Study Group.
Akaza H; Aso Y; Koiso K; Fuse H; Isurugi K; Okada K; Usami M; Kotake T; Ohashi T; Ueda T
J Int Med Res; 1990; 18 Suppl 1():90-102. PubMed ID: 2108889
[TBL] [Abstract][Full Text] [Related]
43. Leuprorelin acetate blood levels and dialysance after the administration of sustained-release leuprorelin acetate in a dialysis case complicated by prostate cancer.
Saruki K; Sekihara T; Mashimo M; Matsuo H; Sekiguchi H
Prostate; 1998 Feb; 34(3):191-4. PubMed ID: 9492847
[TBL] [Abstract][Full Text] [Related]
44. Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin.
Snelder N; Drenth HJ; Riber Bergmann K; Wood ND; Hibberd M; Scott G
Br J Clin Pharmacol; 2019 Jun; 85(6):1247-1259. PubMed ID: 30731514
[TBL] [Abstract][Full Text] [Related]
45. [Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot].
Jiménez Cruz JF; Vera Donoso CD; Iborra I; Solsona E; Forner E; Villavicencio H; Díaz C; González C; Rioja L; Pertusa C
Actas Urol Esp; 1994 Feb; 18(2):90-3. PubMed ID: 7976707
[TBL] [Abstract][Full Text] [Related]
46. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
47. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
Navratil H
J Int Med Res; 1990; 18 Suppl 1():69-73. PubMed ID: 2108887
[TBL] [Abstract][Full Text] [Related]
48. Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate.
Okada H; Doken Y; Ogawa Y
J Pharm Sci; 1996 Oct; 85(10):1044-8. PubMed ID: 8897268
[TBL] [Abstract][Full Text] [Related]
49. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
[TBL] [Abstract][Full Text] [Related]
50. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
Tsushima T; Nasu Y; Saika T; Maki Y; Noda M; Suyama B; Yamato T; Kumon H
Urol Int; 2001; 66(3):135-9. PubMed ID: 11316974
[TBL] [Abstract][Full Text] [Related]
51. Injection-site granulomas due to the administration of leuprorelin acetate for the treatment of prostatic cancer.
Shiota M; Tokuda N; Kanou T; Yamasaki H
Fukuoka Igaku Zasshi; 2007 Jul; 98(7):301-4. PubMed ID: 17710895
[TBL] [Abstract][Full Text] [Related]
52. What should I know about Lupron Depot for treating prostate cancer?
Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
[No Abstract] [Full Text] [Related]
53. Injection systems for two luteinising hormone-releasing hormone agonists: a comparative assessment of administration times and nurses' perceptions.
Morgan G; Cooley C
Eur J Oncol Nurs; 2005 Dec; 9(4):334-40. PubMed ID: 16298160
[TBL] [Abstract][Full Text] [Related]
54. [Psychological impact of prostate cancer on patients receiving a 6-month androgen deprivation therapy].
de la Taille A; Mardoyan S; Lafaye A
Prog Urol; 2018 Jan; 28(1):32-38. PubMed ID: 29223415
[TBL] [Abstract][Full Text] [Related]
55. Benefits of less frequent injections in advanced prostate cancer.
Ortiz M
Aust Fam Physician; 2015 Jun; 44(6):429-30. PubMed ID: 26209999
[TBL] [Abstract][Full Text] [Related]
56. Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer. Takeda NHT Italian Group.
Prezioso D; Lotti T; Montironi R; Polito M
Urol Int; 1998; 60 Suppl 2():11-7; discussion 35. PubMed ID: 9607553
[TBL] [Abstract][Full Text] [Related]
57. Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer.
Bourdin S; Karam G; Clemain P; Bouchot O; Peuvrel P; Lacoste J; Auvigne J
J Int Med Res; 1990; 18 Suppl 1():74-8. PubMed ID: 2108888
[TBL] [Abstract][Full Text] [Related]
58. [Surgical management of inflammatory granuloma which developed following subcutaneous injection of leuprorelin acetate: a case report].
Oida T; Shichiri Y; Takao N; Kanno T; Kanamaru H
Hinyokika Kiyo; 2005 Jul; 51(7):487-9. PubMed ID: 16119817
[TBL] [Abstract][Full Text] [Related]
59. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
Stolz W; Pfützenreuter N
Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
[TBL] [Abstract][Full Text] [Related]
60. Anaphylaxis to leuprolide acetate depot injection during treatment for prostate cancer.
Grant JP; Levinson AW
Clin Genitourin Cancer; 2007 Mar; 5(4):284-6. PubMed ID: 17553209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
